2025, Vol. 7, Issue 4, Part A

Author(s): Nur Nahar Ayrin, Abdullah Al Faruk, Moshiul Alam, Mobarak Hossain, Sadia Afroz and Tahmid Oyon

Abstract: Background: Urinary tract infection (UTI) remains one of the most frequent bacterial infections globally, with rising antimicrobial resistance posing major therapeutic challenges. Continuous surveillance at the institutional level is essential to guide empirical therapy.
Objective: To evaluate the distribution of uropathogens and their antimicrobial resistance (AMR) profiles among patients diagnosed with UTI in a tertiary care hospital.
Methods: This cross-sectional study included 75 culture-positive UTI cases over a 12-month period. Midstream urine samples were processed using standard microbiology techniques. Organisms were identified, and antimicrobial susceptibility was performed using Kirby-Bauer disc diffusion following CLSI guidelines. Demographic data, pathogen prevalence, and resistance trends were analyzed.
Results: Of the 75 cases, females constituted 68% and males 32%. Escherichia coli was the predominant pathogen (61.3%), followed by Klebsiella spp. (16%), Enterococcus spp. (10.6%), Pseudomonas aeruginosa (6.6%), and Proteus spp. (5.3%). E. coli exhibited high resistance to ampicillin (82.6%), ciprofloxacin (71.7%), and trimethoprim-sulfamethoxazole (64.1%), while showing lower resistance to nitrofurantoin (13%), amikacin (17%), and carbapenems (9%). Klebsiella spp. showed significant resistance to third-generation cephalosporins (79%) and fluoroquinolones (65%).
Conclusion: E. coli remains the leading UTI pathogen with alarming resistance to first-line antibiotics. Nitrofurantoin, amikacin, and carbapenems remain effective options. Regular AMR surveillance is crucial to guide empirical treatment and restrict further resistance development

DOI: 10.22271/27069567.2025.v7.i4a.682

Pages: 47-50 | Views: 142 | Downloads: 55

Download Full Article: Click Here